On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards for China and Best Practices were grandly announced at the 2025 Frost & Sullivan Global Growth, Innovation and Leadership Awards Ceremony and VIP Reception.
Based on the research and analysis of the Chinese medical aesthetics product technology market in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded Frost & Sullivan China's 2025 Medical Aesthetics Product Technology Innovation Award to RuiRX Biomedical (Shenzhen) Co., Ltd. (hereinafter referred to as 'RuiRX Biomedical'). Wang Chenhui, Managing Partner and President of Frost & Sullivan Greater China, and Wang Tingfu, Chairman of Xingfu Capital and an expert advisor to the Frost & Sullivan Global Expert Advisory Group, presented the award on behalf of RuiRX Biomedical (Shenzhen) Co., Ltd.
RuiXin Biomedical (Shenzhen) Co., Ltd.
"2025 China Medical Beauty Product Technology Innovation Award"
Wang Chenhui, Managing Partner and President of Frost & Sullivan Greater China, and Wang Tingfu, Chairman of Xingfu Capital and an expert advisor to the Frost & Sullivan Global Expert Advisory Group, presented awards on behalf of Ruiyan Biomedical (Shenzhen) Co., Ltd.
Deeply involved in full-layer medical aesthetics filling, setting a new benchmark for bionic shaping
Ruiyin Biotechnology focuses on public hospital plastic surgery, dermatology, and high-quality private medical aesthetics institutions. It targets the mid-to-high-end female customer group who pursue natural, safe, and long-lasting results, offering a full range of filling solutions covering superficial, intermediate, and deep layers. Relying on the core platform of "polysaccharide-protein bionic interpenetrating matrix," the company uses molecular editing bionic technology to achieve "low-viscosity injection - high-position shaping" that is highly compatible with tissues. It has invested a total of 80 million yuan in research and development, constructing multiple patent barriers, and ensuring that its technology is difficult to replicate through customized equipment and stable production capabilities throughout the entire process. Compared with domestic and international competitors, its products have formed significant differentiated advantages in terms of tissue compatibility, shaping stability, and postoperative comfort.
Three categories of devices accelerate transformation, with functional skincare taking the lead in commercialization
Currently, RuiRan Biotech's Class III medical device products are advancing through production transformation and multi-center clinical trials. The functional skincare product has completed commercialization and gained a high reputation for repeat purchases in promoting skin health and anti-aging; it is expected that two devices will complete pilot production-to-scale production and one will complete clinical trials within the year, providing strong momentum for the company's future performance growth.
Adhere to differentiated innovation and promote the high-quality leapfrog development of the medical beauty industry
Facing the challenges of industry homogenization and price decline, RuiRan Biotechnology continues to increase its investment in scientific research. It has jointly established an 'Molecular Bionics Joint Laboratory' with domestic and international universities, research institutes, and industry chain partners to accelerate the clinical transformation of next-generation regenerative materials and delivery technologies. In the future, the company will take 'to make users beautiful and healthy! Beautiful and natural!' as its mission. By continuously launching innovative products, it will lead the medical aesthetics industry towards a higher level of bionics and regenerative medicine, helping to build a multi-level and sustainable medical aesthetics consumption pattern.
About Frost & Sullivan China Innovation Award
The Frost & Sullivan China Innovation Award recognizes outstanding performance and achievements in technological innovation, market potential, customer service, brand, and other aspects by enterprises. The Frost & Sullivan team, through in-depth interviews, industry analysis, secondary research, and other methods, nominated a competitive group of excellent companies to the independent judging panel. An independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and renowned listed entrepreneurs conducted a rigorous review of the companies nominated by the Frost & Sullivan team and decided to award the '2025 China Medical Beauty Product Technological Innovation Award' to RuiRX Biomedical (Shenzhen) Co., Ltd.
